Novartis Ag (NVS) Other Accumulated Expenses (2009 - 2026)

Novartis Ag's Other Accumulated Expenses history runs 17 years deep, the most recent figure standing at -$100.0 million for Q1 2026.

• In Q1 2026, Other Accumulated Expenses changed N/A year-over-year to -$100.0 million; the TTM figure through Mar 2026 stood at -$100.0 million (changed N/A YoY), while the FY2023 annual figure was $516.0 million, down 38.28% from the prior year.
• Other Accumulated Expenses came in at -$100.0 million for Q1 2026 at Novartis Ag, down from -$23.0 million in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $2.6 billion in Q2 2022 to a low of -$100.0 million in Q1 2026.
• A 4-year average of $774.0 million and a median of $320.5 million in 2022 frame the typical range for Other Accumulated Expenses.
• Across the five-year window, Other Accumulated Expenses soared 35.06% in 2022 and sank 360.0% in 2024, its largest moves.
• Novartis Ag's Other Accumulated Expenses stood at $836.0 million in 2022, then slumped by 38.28% to $516.0 million in 2023, then plunged by 104.46% to -$23.0 million in 2024, then sank by 334.78% to -$100.0 million in 2026.
• According to Business Quant data, Other Accumulated Expenses over the past three periods registered -$100.0 million, -$23.0 million, and $516.0 million for Q1 2026, Q1 2024, and Q4 2023 respectively.

Peer Comparison